SABS Share Price Performance
US$3.96
1.46 (58.39%)
63.3% undervalued intrinsic discount
US$10.80
Fair Value
Price US$3.96
AnalystConsensusTarget US$10.80
AnalystHighTarget US$15.00
Fair ValueUS$10.80
Share Pricen/a
New Narrative • Jun 16
SAB Biotherapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
SABS Community Narratives
AN
Fair Value
·Fair Value US$10.8 63.3% undervalued intrinsic discount
Phase IIb Safeguard Trial And Autoimmune Shift Will Redefine Long Term Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$15 73.6% undervalued intrinsic discount
Autoimmune Disease Modifying Therapies And Regulatory Tailwinds Will Support Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Phase IIb Safeguard Trial And Autoimmune Shift Will Redefine Long Term Potential
A small biotech is betting that its experimental immune therapy can slow down type 1 diabetes soon after diagnosis, and a key mid-stage study is now recruiting patients across multiple countries. Clearer guidance from regulators and early signs the treatment may be repeatable without serious reactions could speed the path to market—if the bigger trial holds up.Read more
AN
US$10.8
63.3% undervalued intrinsic discount
Fair Value
Profit Margin
18.98%
Future PE
238.61x
Price in 2029
US$0
Autoimmune Disease Modifying Therapies And Regulatory Tailwinds Will Support Long Term Upside Potential
SAB Biotherapeutics is betting that the next wave of type one diabetes care will focus on slowing the disease itself, not just managing daily symptoms. Regulators appear to be opening a clearer path for this kind of treatment, but the story still hinges on one lead program delivering clean results and scaling smoothly.Read more
AN
US$15
73.6% undervalued intrinsic discount
Fair Value
Profit Margin
19.04%
Future PE
230x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Phase IIb Safeguard Trial And Autoimmune Shift Will Redefine Long Term Potential
Fair Value: US$10.8 63.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Autoimmune Disease Modifying Therapies And Regulatory Tailwinds Will Support Long Term Upside Potential
Fair Value: US$15 73.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
SAB Biotherapeutics, Inc. Key Details
About SABS
- Founded
- 2014
- Employees
- 86
- CEO
- WebsiteView website
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
